
TScan Therapeutics, Inc. (NASDAQ:TCRX – Free Report) – Stock analysts at HC Wainwright cut their FY2026 earnings estimates for shares of TScan Therapeutics in a research note issued to investors on Friday, November 13th. HC Wainwright analyst A. Maldonado now expects that the company will earn ($0.84) per share for the year, down from their prior forecast of ($0.62). HC Wainwright currently has a “Neutral” rating and a $1.00 target price on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($0.87) per share. HC Wainwright also issued estimates for TScan Therapeutics’ Q4 2026 earnings at ($0.13) EPS, Q1 2027 earnings at ($0.10) EPS, Q2 2027 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.09) EPS, Q4 2027 earnings at ($0.09) EPS, FY2027 earnings at ($0.37) EPS, FY2028 earnings at ($0.28) EPS and FY2029 earnings at ($0.28) EPS.
TScan Therapeutics (NASDAQ:TCRX – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.06). TScan Therapeutics had a negative return on equity of 140.75% and a negative net margin of 2,219.19%. The company had revenue of $0.59 million for the quarter, compared to the consensus estimate of $0.46 million.
Check Out Our Latest Report on TCRX
TScan Therapeutics Stock Down 1.7%
TCRX opened at $0.15 on Tuesday. The stock has a market cap of $10.06 million, a PE ratio of -0.17 and a beta of 1.21. The company has a quick ratio of 2.03, a current ratio of 2.03 and a debt-to-equity ratio of 0.45. TScan Therapeutics has a 52 week low of $0.14 and a 52 week high of $1.47. The business’s fifty day simple moving average is $0.25 and its 200 day simple moving average is $0.79.
Institutional Trading of TScan Therapeutics
Several hedge funds have recently added to or reduced their stakes in TCRX. Bank of America Corp DE raised its position in TScan Therapeutics by 48.7% during the 1st quarter. Bank of America Corp DE now owns 57,529 shares of the company’s stock valued at $58,000 after purchasing an additional 18,829 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new stake in TScan Therapeutics in the 2nd quarter worth approximately $25,000. Public Employees Retirement System of Ohio purchased a new stake in TScan Therapeutics in the 1st quarter worth approximately $28,000. Kestra Advisory Services LLC bought a new stake in shares of TScan Therapeutics in the 1st quarter worth approximately $63,000. Finally, NewEdge Wealth LLC bought a new stake in shares of TScan Therapeutics in the 2nd quarter worth approximately $90,000. 82.83% of the stock is owned by institutional investors.
About TScan Therapeutics
TScan Therapeutics is a clinical-stage biotechnology company developing engineered T cell receptor (TCR) T cell therapies for cancer. Its approach is designed to equip a patient’s T cells to recognize and attack cancer cells bearing specific targets. The company’s research and development programs include therapies for blood cancers and solid tumors. TScan uses its technology platform to identify cancer-associated targets and develop TCRs directed at them, with the goal of creating treatments for patients whose cancers express those targets.
Featured Articles
- Five stocks we like better than TScan Therapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
